

First major licensing deal for an exosome therapeutics in Korea

February 20, 2025 | News

Brexogen and BMI Korea enter strategic deal worth \$2.3 M for Exosome Therapeutics



Brexogen, a leading biotechnology company specialising in exosome-based therapeutics, has announced a technology transfer and licensing agreement with BMI Korea for BxC-I17e, an innovative exosome-based injectable therapeutic.

This agreement marks the first major licensing deal for an exosome therapeutic in Korea, signifying a major milestone in the commercialization of exosome-based medicines.

BxC-I17e is a key asset in Brexogen's pipeline and is currently undergoing clinical trials in the United States for atopic dermatitis. Recognising its broader therapeutic potential, BMI Korea has secured rights to expand its development into potential indications excluding immunological indications, covering both domestic and key export markets.

While financial terms remain confidential, Brexogen will receive KRW 3 billion (approximately \$2.3 million) as a non-refundable upfront payment.

BMI Korea, a pharmaceutical company with annual revenues exceeding KRW 100 billion (\$77 million), specialises in prescription drugs, biologics, medical devices, and aesthetic products. The company operates large-scale contract manufacturing (CMO) facilities in Jeju and Osong, Chungbuk, with extensive expertise in regulatory approvals, production, and commercialization.

Under this partnership, BxC-I17e will be manufactured at BMI Korea's cutting-edge facilities, ensuring scalability for both clinical and commercial supply.

To date, globally, there is no approved exosome-based therapeutics for commercial use. This partnership is expected to drive innovation in exosome drug development and set new industry standards.

Founded in 2019, Brexogen's flagship programme, BRE-AD01 for atopic dermatitis, is currently in Phase 1 clinical trials in the U.S.

Brexogen has also successfully commercialised BREXTEM-S (for skin rejuvenation) and BREXTEM-H (for hair restoration), offering exosome-based solutions for clinical and hospital use. Looking ahead, Brexogen is actively preparing for its KOSDAQ

listing in 2026, with Korea Investment & Securities serving as the lead underwriter.